SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust (SLV) is experiencing intense bullish momentum, driven by spot silver prices reaching new all-time highs. This rally is fueled by tightening global supply due to upcoming Chinese export restrictions, alongside booming industrial demand from EV batteries, solar, and AI data centers. The community is actively discussing a potential 'silver squeeze' and a significant re-rating of silver's value, though some anticipate a near-term pullback after its rapid ascent.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta (KTA) is a trending Layer-1 network following the live launch of its fiat anchor with a Stripe company, seamlessly bridging traditional finance with crypto. The community is actively discussing its high-performance, compliance-first architecture, boasting over 11 million transactions per second and a strong focus on Real World Asset tokenization. Many believe KTA is an undervalued infrastructure play poised for significant institutional adoption and robust cross-chain payments.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is actively trending following the FDA approval of YARTEMLEA, a groundbreaking therapy for transplant-associated thrombotic microangiopathy, which is the first and only approved treatment for the condition. The community is buzzing with enthusiasm, anticipating significant value appreciation and a potential short squeeze, further bolstered by the company's substantial partnership with Novo Nordisk.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony (UAMY) is trending amid escalating geopolitical tensions driving the US government's urgent push for domestic critical mineral independence, especially following China's tightened export controls on antimony. The community is buzzing about UAMY's unique position as the sole US provider of military-grade antimony, reinforced by significant defense contracts and ongoing capacity expansion. Despite recent price volatility, investors are anticipating major government grants or an acquisition, believing the stock remains significantly undervalued given its strategic importance.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet is trending as strategic moves in AI and autonomous technology draw significant attention. The company's acquisition of Intersect Power reinforces its commitment to scaling AI infrastructure, complemented by high valuation discussions for its Waymo autonomous driving unit. Community sentiment is largely bullish, recognizing Gemini's growing market share against rivals and Alphabet's strong position as a leading AI innovator with proprietary hardware.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing a significant rally following exceptionally strong earnings and robust guidance, largely driven by surging demand for High-Bandwidth Memory (HBM) essential for AI data centers. The market is buzzing with bullish sentiment, with many anticipating further price appreciation as memory shifts from a cyclical commodity to a critical, high-margin component in the burgeoning AI landscape. Community discussions highlight strong conviction in its growth potential, comparing it to other successful AI plays amid reports of rising HBM prices and a scramble by big tech for long-term supply.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is currently trending due to an approaching significant options expiry, igniting fervent debate among the community about its immediate price trajectory. Bulls anticipate a potential 'Santa rally' and short squeeze, while bears caution about a 'fake pump' and further market correction, with many keenly watching how institutional and retail players position themselves around this event.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash (BCH) is trending amid community discussion around its integration-ready Post-Quantum Vault and rumors of substantial institutional accumulation. Sentiment is polarized, with many anticipating a significant breakout and an altcoin season led by BCH due to perceived undervaluation and technical signals. However, others dismiss its potential, questioning its long-term growth and comparing it unfavorably to other crypto assets.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending amid a bullish outlook for U.S. drone manufacturers, fueled by the FCC's immediate implementation of a ban on foreign-made drones and components. The community is buzzing with anticipation for major defense contracts, as a new defense bill is poised to unlock substantial government spending for unmanned aerial and surface systems. Discussions highlight RCAT's production capacity and potential for its Black Widow and Blue Ops USVs to capture significant market share.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is a focal point of discussion, driven by the FDA's approval of Novo Nordisk's oral Wegovy and expectations of a potential partnership that could significantly impact Hims' expanding weight-loss offerings. While proposed legislation concerning compounded GLP-1s and high short interest generate debate, many in the community view recent price movements as a compelling buying opportunity, emphasizing the company's robust fundamentals, institutional backing, and strategic growth into new verticals and international markets.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FDA Issues CRL to SNY's Regulatory Filing for Multiple Sclerosis Drug

Sanofi receives an FDA CRL for tolebrutinib in nrSPMS after multiple review extensions. The EC clears Wayrilz for treating immune thrombocytopenia.

AGIO's Mitapivat Gets FDA Nod for Thalassemia Indication with REMS in Label

Agios Pharmaceuticals wins FDA approval for Aqvesme in alpha- and beta-thalassemia, making mitapivat the only approved option, despite a new REMS.

Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise

SNY's $2.2 billion deal for Dynavax adds Heplisav-B, a shingles candidate, and other vaccine programs, strengthening its adult vaccine franchise and pipeline.

What Makes Castle Biosciences (CSTL) a Good Fit for 'Trend Investing'

Castle Biosciences (CSTL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

GILD Exercises Option to License Assembly Bio's Herpes Programs

Gilead exercises its option to license ASMB's HSV programs for developing long-acting candidates, ABI-1179 & ABI-5366, for recurrent genital herpes.

CRSP Stock Rises on Encouraging Early Data From Zugo-Cel Studies

CRISPR Therapeutics shares jump after early zugo-cel study data show sustained B-cell depletion and early efficacy across autoimmune and cancer studies.

JNJ's Tremfya Gets EU Approval for Pediatric Plaque Psoriasis

Johnson & Johnson wins EU approval for Tremfya in pediatric plaque psoriasis, making it the first IL-23 inhibitor cleared for any pediatric condition.

AZN, Daiichi's Enhertu Gets FDA Nod for First-Line Breast Cancer (Revised)

AstraZeneca's Enhertu wins FDA nod as a first-line treatment for HER2-positive metastatic breast cancer.

AZN, Daiichi's Enhertu Gets Breakthrough Tag for Expanded Cancer Use

AstraZeneca's Enhertu wins FDA Breakthrough tag for expanded use in breast cancer, while a late-stage study on ceralasertib + Imfinzi in lung cancer misses its goal.

Castle Biosciences (NASDAQ:CSTL) Hits New 12-Month High After Analyst Upgrade

Castle Biosciences (NASDAQ:CSTL) Sets New 1-Year High After Analyst Upgrade...

Castle Biosciences, Inc.is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett’s esophagus, uveal melanoma, and in the treatment of mental health conditions. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.34	--	--	N/A
Q3 '25	-$0.52	-$0.02	96.16%	BEAT
Q2 '25	-$0.53	$0.15	128.24%	BEAT
Q1 '25	-$0.07	-$0.90	-1195.95%	MISSED
Q4 '24	$0.05	$0.32	579.25%	BEAT

CSTL
Castle Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest CSTL News

CSTLCastle Biosciences Inc